Cumberland Pharmaceuticals
CPIX
33 hedge funds and large institutions have $30.6M invested in Cumberland Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 0 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
10% more funds holding
Funds holding: 30 → 33 (+3)
0.25% more ownership
Funds ownership: 34.15% → 34.41% (+0.25%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less capital invested
Capital invested by funds: $32.9M → $30.6M (-$2.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$88.7K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$33.4K |
| 3 |
Renaissance Technologies
New York
|
+$25.1K |
| 4 |
JP Morgan Chase
New York
|
+$22.8K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$16.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
-$86.8K |
| 2 |
BlackRock
New York
|
-$83K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$63.3K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$30.9K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
-$16.5K |
CPIX Hedge Fund Activity: Q3 2018 in Review
33 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q3 2018, worth a combined $30.6M — down 7% from $32.9M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CPIX positions and 0 closed out — a net gain of 3 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $88.7K. The largest seller was Ariel Investments, cutting an estimated $86.8K.
- 33 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q3 2018, up from 30 in Q2 2018.
- Funds reported $30.6M of Cumberland Pharmaceuticals stock for Q3 2018, down 7% quarter-over-quarter.
- 3 funds opened new Cumberland Pharmaceuticals positions in Q3 2018 and 0 closed out, a net change of +3 holders.
- The largest Cumberland Pharmaceuticals buyer in Q3 2018 was Stonepine Capital Management, an estimated $88.7K added.
- The largest Cumberland Pharmaceuticals seller in Q3 2018 was Ariel Investments, an estimated $86.8K sold.
Based on aggregated 13F filings for Q3 2018.